Hans Michael Eggenweiler

Title: The Innovations of Hans Michael Eggenweiler

Introduction

Hans Michael Eggenweiler is a notable inventor based in Darmstadt, Germany. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target critical pathways in cancer and inflammatory diseases. With a total of 4 patents, his work has garnered attention in both academic and industrial circles.

Latest Patents

Among his latest patents, Eggenweiler has developed Furo[3,2-b]- and thieno[3,2-b]pyridin derivatives. These compounds are recognized as inhibitors of TBK1 and IKKε, making them valuable for the treatment of cancer and inflammatory diseases. Additionally, he has created novel quinazoline derivatives, which serve as HSP90 inhibitors. These derivatives can be utilized in the preparation of medicaments aimed at treating diseases where the modulation of HSP90 is crucial.

Career Highlights

Throughout his career, Eggenweiler has worked with prominent organizations, including Merck Patent GmbH and Merck Patent Gesellschaft mit beschränkter Haftung. His experience in these companies has allowed him to refine his expertise in patent development and innovation in pharmaceutical compounds.

Collaborations

Eggenweiler has collaborated with several professionals in his field, including Christian Sirrenberg and Hans Peter Buchstaller. These collaborations have contributed to the advancement of his research and the successful development of his patented compounds.

Conclusion

Hans Michael Eggenweiler's contributions to medicinal chemistry and his innovative patents highlight his role as a significant figure in the field. His work continues to impact the development of treatments for critical health issues.